Oral Tau-Targeting Therapy Fails to Slow Early Alzheimer Disease Progression
KEY TAKEAWAYS
- Oral ceperognastat failed to slow clinical progression in individuals with early symptomatic Alzheimer disease and did not meet the trial's primary efficacy end point.
- Favorable changes in MRI and limited tau PET measures seen in those treated with ceperognastat did not translate into improvements in cognition or function in study participants.
Results from a randomized virtual trial presented at the 2026 Alzheimer's Association International Conference (AAIC) and published simultaneously in JAMA showed that the investigational oral tau-targeting therapy ceperognastat (Eli Lilly and Company, Indianapolis, IN) failed to slow clinical progression in patients with early symptomatic Alzheimer disease. Although the drug demonstrated favorable effects on selected imaging biomarkers in trial participants, it did not improve clinical outcomes compared with those taking placebo. Eli Lilly also announced that development of ceperognastat for Alzheimer disease will not continue based on the phase 2 findings.
The multicenter, randomized, double-blind, placebo-controlled trial enrolled 327 participants with early symptomatic Alzheimer disease across 72 sites in Australia, Canada, Japan, Poland, and the United States. Participants had biomarker-confirmed tau pathology and were randomized to once-daily oral ceperognastat (0.7 or 3 mg) or placebo for 100 weeks. The primary efficacy analysis included 259 participants with low to medium baseline tau burden, the population prespecified as most likely to benefit from treatment. Mean participant age was approximately 74 years, and about 62% were women.
Results
The trial did not meet its primary endpoint. At 100 weeks, ceperognastat did not produce clinically meaningful slowing of decline on the Integrated Alzheimer's Disease Rating Scale (iADRS). Compared with placebo, the lower dose was associated with an estimated 16% less clinical progression, while the higher dose was associated with 32% greater progression; neither met the prespecified Bayesian success criterion. No benefit was observed across secondary clinical measures, including the Clinical Dementia Rating–Sum of Boxes, Alzheimer's Disease Assessment Scale–Cognitive Subscale, Mini-Mental State Examination, or activities of daily living.
Investigators did observe biologic effects. The higher dose modestly reduced tau PET progression in one brain region, and both doses were associated with significantly less whole-brain volume loss on MRI than placebo. However, these imaging findings did not translate into measurable clinical benefit. In addition, the 3-mg dose was associated with more serious and severe adverse events than placebo.
Source
Fleisher AS, Munsie L, Mancini M, et al. Ceperognastat in Early Symptomatic Alzheimer Disease: A Randomized Clinical Trial. JAMA. Published online July 13, 2026. doi:10.1001/jama.2026.12768.